Ignite Creation Date:
2024-05-06 @ 3:44 PM
Last Modification Date:
2024-10-26 @ 1:55 PM
Study NCT ID:
NCT04733404
Status:
RECRUITING
Last Update Posted:
2022-03-29
First Post:
2021-01-27
Brief Title:
Safety and Effectiveness Study of Dragonfly System for Functional Mitral Regurgitation
Sponsor:
Hangzhou Valgen Medtech Co Ltd
Organization:
Hangzhou Valgen Medtech Co Ltd
Study Overview
Official Title:
A Prospective Multicenter Objective Performance Criteria Study to Evaluate the Safety and Effectiveness of Dragonfly Transcatheter Mitral Valve Repair System for the Treatment of Functional Mitral Regurgitation FMR Subjects
Status:
RECRUITING
Status Verified Date:
2021-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To confirm the effectiveness and safety of the Dragonfly transcatheter mitral valve repair system for the treatment of chronic moderate to severe 3 or severe 4 functional mitral regurgitation FMR who remained clinically symptomatic after guideline-directed medical treatment
Detailed Description:
This study is a prospective multicenter objective performance criteria design Patients are chronic moderate to severe 3 or severe 4 functional mitral regurgitation FMR who remained clinically symptomatic after guideline-directed medical treatment After signing an informed consent form subjects are enrolled and treated with the DragonFly Transcatheter Mitral Valve Repair System All subjects receive clinical follow-up immediately after procedure before discharge 30 days after procedure 6 months after procedure and 12 months after procedure
The primary outcome is defined as a composite measure include all-cause mortality and recurrent heart failure hospitalization at 12 months after procedure
The secondary outcomes include acute procedural success acute device success mitral regurgitation degree MR2 recurrent heart failure hospitalization NYHA class I or II at 30 days 6 months and 12 months and the improvement in 6 minutes walk test distance left ventricular end-diastolic volume quality of life change as assessed by the Kansas City Cardiomyopathy Questionnaire KCCQ score from baseline at 12 months after procedure
The safety endpoints include major adverse events MAEs at 30 days and 12 months after procedure and all-cause mortality cardiac mortality at 30 days 6 months and 12 months after procedure
To evaluate the safety and effectiveness of the Valgen Medtech DragonFly Transcatheter Mitral Valve Repair System in the treatment of patients with chronic moderate to severe 3 or severe 4 functional mitral regurgitation FMR who remained clinically symptomatic after guideline-directed medical treatment and to evaluate the product performance
The primary outcome is defined as a composite measure include all-cause mortality and recurrent heart failure hospitalization at 12 months after procedure
The secondary outcomes include acute procedural success acute device success mitral regurgitation degree MR2 recurrent heart failure hospitalization NYHA class I or II at 30 days 6 months and 12 months and the improvement in 6 minutes walk test distance left ventricular end-diastolic volume quality of life change as assessed by the Kansas City Cardiomyopathy Questionnaire KCCQ score from baseline at 12 months after procedure
The safety endpoints include major adverse events MAEs at 30 days and 12 months after procedure and all-cause mortality cardiac mortality at 30 days 6 months and 12 months after procedure
To evaluate the safety and effectiveness of the Valgen Medtech DragonFly Transcatheter Mitral Valve Repair System in the treatment of patients with chronic moderate to severe 3 or severe 4 functional mitral regurgitation FMR who remained clinically symptomatic after guideline-directed medical treatment and to evaluate the product performance
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None